Ethical issues in oncology biostatistics
From MaRDI portal
Publication:5424159
DOI10.1191/0962280202sm301razbMath1121.62670OpenAlexW1970489508WikidataQ52944236 ScholiaQ52944236MaRDI QIDQ5424159
Publication date: 2 November 2007
Published in: Statistical Methods in Medical Research (Search for Journal in Brave)
Full work available at URL: https://doi.org/10.1191/0962280202sm301ra
Cites Work
- The two-armed bandit with delayed responses
- Investigating therapies of potentially great benefit: ECMO. With comments and a rejoinder by the author
- Ethics and statistics in randomized clinical trials. With comments and a rejoinder by the author
- Monitoring the Rates of Composite Events with Censored Data in Phase II Clinical Trials
- Group Sequential Tests for Bivariate Response: Interim Analyses of Clinical Trials with Both Efficacy and Safety Endpoints
- Designs for Phase II Trials Allowing for a Trade-Off between Response and Toxicity
- Incorporating Toxicity Considerations Into the Design of Two-Stage Phase II Clinical Trials
- Coupled Error Spending Functions for Parallel Bivariate Sequential Tests
- A consistent estimator for the distribution of quality adjusted survival time
- Selecting Therapeutic Strategies Based on Efficacy and Death in Multicourse Clinical Trials
- Treatment Comparisons Based on Two‐Dimensional Safety and Efficacy Alternatives in Oncology Trials
- Decision Theoretic Designs for Phase II Clinical Trials with Multiple Outcomes
- Approximate Bayesian Evaluation of Multiple Treatment Effects
- Sequential Designs for Phase I Clinical Trials with Late‐Onset Toxicities
This page was built for publication: Ethical issues in oncology biostatistics